Loading organizations...
§ Venture Capital · Dublin, Dublin, Ireland
Biopharmaceutical company developing impactful therapeutics, likely focusing on CNS, women's health, and opioid overdose.
AixThera is an investment firm focused on funding and supporting the development of novel therapeutics designed to significantly improve patient lives. The firm employs a strategic investment model, leveraging the deep industry expertise of its leadership to cultivate promising biopharmaceutical innovations towards market readiness.
Established in 2019, AixThera was founded by highly experienced pharmaceutical executives: Seamus Mulligan, David Brabazon, Eunan Maguire, Declan Brides, and Fintan Keegan. These founders, veterans from successful companies such as Adapt Pharma, Azur Pharma, and Jazz Pharmaceuticals, recognized a critical need for hands-on investment to accelerate impactful drug development.
AixThera primarily backs emerging biopharmaceutical companies and therapeutic research programs. Its vision is to accelerate the introduction of transformative medical treatments globally, reshaping patient care. The firm combines strategic capital with deep operational and commercial guidance for its portfolio to achieve this objective.
AixThera has 1 tracked investment across 1 company. The latest tracked deal is $30.0M Series A in Ochre Bio in October 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2022 | Ochre Bio | $30.0M Series A | — | Apollo Health Ventures, BoxOne Ventures, Aniq Kassam, Hoxton Ventures, Khosla Ventures, Alice Zhang, Kristen Fortney, Martin Chavez, Backed, Hermes Epitek, LifeForce Capital, Lifelink, Selvedge |